JP2013528570A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528570A5
JP2013528570A5 JP2013502023A JP2013502023A JP2013528570A5 JP 2013528570 A5 JP2013528570 A5 JP 2013528570A5 JP 2013502023 A JP2013502023 A JP 2013502023A JP 2013502023 A JP2013502023 A JP 2013502023A JP 2013528570 A5 JP2013528570 A5 JP 2013528570A5
Authority
JP
Japan
Prior art keywords
group
region
groups
moiety
intact antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013502023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/051373 external-priority patent/WO2011121560A2/en
Publication of JP2013528570A publication Critical patent/JP2013528570A/ja
Publication of JP2013528570A5 publication Critical patent/JP2013528570A5/ja
Pending legal-status Critical Current

Links

JP2013502023A 2010-03-31 2011-03-31 安定化された抗体調製物およびその使用 Pending JP2013528570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31931310P 2010-03-31 2010-03-31
US61/319,313 2010-03-31
PCT/IB2011/051373 WO2011121560A2 (en) 2010-03-31 2011-03-31 Stabilized antibody preparations and uses thereof

Publications (2)

Publication Number Publication Date
JP2013528570A JP2013528570A (ja) 2013-07-11
JP2013528570A5 true JP2013528570A5 (enExample) 2014-04-24

Family

ID=44543567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502023A Pending JP2013528570A (ja) 2010-03-31 2011-03-31 安定化された抗体調製物およびその使用

Country Status (5)

Country Link
US (1) US20130028920A1 (enExample)
EP (1) EP2552482A2 (enExample)
JP (1) JP2013528570A (enExample)
CA (1) CA2794631A1 (enExample)
WO (1) WO2011121560A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
JP2013523717A (ja) * 2010-03-31 2013-06-17 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
FR2995214B1 (fr) * 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CA3061467A1 (en) * 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2019018747A1 (en) * 2017-07-20 2019-01-24 Trustees Of Boston University DETECTION ASSAY OF TENOFOVIR
WO2020047067A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
AU3722984A (en) 1984-01-05 1985-07-11 Manlab Pty. Ltd. Reagents for immunoassay at elevated temperatures
US4808705A (en) 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
WO2002060484A1 (en) * 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
WO2003061568A2 (en) * 2002-01-16 2003-07-31 Eliezer Rapaport Methods and therapeutic compositions in the treatment of advanced cancer
EP1592813B1 (en) * 2003-01-30 2012-12-26 BellBrook Labs, LLC Assay method for group transfer reactions
JP2006516636A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
EP2073826A4 (en) * 2006-10-17 2010-12-15 Dyax Corp SEQUENTIAL COMBINATION THERAPY
EP2586788B1 (en) * 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2010132047A1 (en) * 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
JP2013523717A (ja) * 2010-03-31 2013-06-17 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用

Similar Documents

Publication Publication Date Title
AU2017339418B2 (en) Benzo[b]thiophene compounds as sting agonists
BR112020007536A2 (pt) anticorpos anti-tau e seus usos
KR102171669B1 (ko) 조합물 및 이의 용도
BR112020003474A2 (pt) composição farmacêutica, e, método para produzir uma composição farmacêutica
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
US20120128666A1 (en) Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
TR201802093T4 (tr) Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu.
JP2018076350A5 (enExample)
JP2018502131A5 (enExample)
UA118760C2 (uk) Заміщені нуклеозиди, нуклеотиди та їх аналоги
JP2007522157A (ja) 抗ｅｇｆｒ抗体の高濃縮液体製剤
CN114533880A (zh) 用ezh2抑制剂治疗mrto/sccoht的方法
WO2023186015A1 (zh) B7h4抗体药物偶联物及其用途
HRP20200032T1 (hr) Antitijelo lijek konjugati
UA123946C2 (uk) Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
JP2013518036A5 (enExample)
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
JP2017537886A5 (enExample)
JP2010535198A (ja) コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物
CA3164800A1 (en) Compound for inhibiting neovascularization factors and use thereof
WO2022171121A1 (zh) 治疗肿瘤的方法和组合
CN109498627A (zh) 一种治疗肿瘤的药物组合物及其应用
JP2013523717A5 (enExample)
WO2025207803A1 (en) Lipid compounds, compositions and methods of use thereof